A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 222 participants.
Also called NCT06647745
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 222 participants
- Sponsor
- THPharm Corp.
- Registry
-
NCT06647745
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- South Korea, Thailand
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06647745. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-10 (actual); primary completion 2026-11-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
- Acronym
- THP-001-031
- Condition
- Type 2 Diabetes
- Condition
- Hypertension
- Intervention (Drug)
- THP-00101
- Intervention (Drug)
- THP-00102
- Intervention (Drug)
- THP-00103
- Intervention (Drug)
- THP-00104
- Intervention (Drug)
- THP-00105
- Intervention (Drug)
- THP-00106
- Lead sponsor
- THPharm Corp.
Record details
- Record id
cardio:ct-nct06647745- Content hash
8af0ff5fde0caba932f90518d88582aa03d0ae5236796c2d368b02fb1397d0f6